Donor Conception and Genetic Disease: Lessons to Be Learned from Donor 7069

The most recent event from PET (the Progress Educational Trust), 'Donor Conception and Genetic Disease: Lessons to Be Learned from Donor 7069', brought together seven perspectives from organisations and experts to discuss the case and its implications.

The online event was chaired by Sarah Norcross, director of PET, who began by explaining the case of donor 7069. His sperm, which unknowingly carried a genetic mutation causing cancer, was used to conceive at least 197 children in 14 countries (see BioNews 1291 and 1319). Some of the children conceived using this sperm have developed cancer, from which some have died. This case raises questions regarding donor screening, the processes after such an incident, and potential limits on the number of offspring per one donor.

The first speaker was Allan Pacey, professor of andrology at the University of Manchester and deputy dean for the Faculty of Biology and Medicine Health. He provided some background on donor screening, explaining that sperm screening has been taking place for at least 80 years, with two central aims: protecting the health of gamete recipients (from communicable diseases) and promoting the health of the future child.

Professor Pacey identified two key issues with screening. First, that genetic screening is performed on donors' blood and not their sperm, and second, that screening significantly reduces the number of donors successfully recruited. He estimated that only around five percent of those who apply are recruited as sperm donors. Screening more intensely will reduce this number further, making it more difficult to access donor gametes.

A counterpart to screening, Professor Pacey explained, is surveillance. Health issues in people born from donor sperm should be reported to the sperm bank, which can investigate if the cause was a genetic issue in the donor.

The second speaker was Dr Edwige Kasper, a cancer geneticist at Rouen University Hospital in France who investigated and classified the genetic variant passed on by donor 7069. Her story started when a doctor asked her lab to classify a variant of unknown significance in the TP53 gene. The doctor's patient had conceived a child using sperm from donor 7069, and had received a letter from the sperm bank indicating that the donor was healthy, but that the variant was present in ten to 19 percent of his sperm cells. The variant's presence in fewer than half of the sperm is the result of mosaicism, which, Dr Kasper explained, is probably why the variant was not detected in the donor's original blood tests.

Dr Kasper and her colleagues classified the variant as 'likely pathogenic'. People inheriting this variant will have Li-Fraumeni syndrome: a hereditary condition associated with increased risk of multiple cancer types, often developing at earlier ages than in unaffected people. As a result, she explained, anyone conceived from this donor's sperm should be tested for the variant, and those carrying it will require annual full-body MRI scans in alternation with brain MRIs and a clinical examination every six months. She also outlined collaborative work with researchers across Europe looking at outcomes for other children of the same donor.

Next was Allan Toft Jacobsen, chief operating officer at the European Sperm Bank, where donor 7069's sperm was held. He explained the chain of reporting involved after such incidents – healthcare professionals report findings to gamete banks, which then assess the information, block the donor, and notify clinics and authorities. The clinics are responsible for informing patients and arranging genetic counselling, while the authorities can issue a rapid European Union (EU) alert and coordinate with national bodies.

Jacobsen explained that the genetic mutation in donor 7069 was not identified through initial screening, but that once the mutation had been identified, the correct procedures were followed. He said that the case illustrated the importance of the reporting system, and that clinics must feed back health issues in donor offspring. 'Some reports we received after the [donor had been blocked] were related to cancer diagnoses more than ten years earlier. Had that information been available when the diagnosis was made, the donor would likely have been assessed and blocked much earlier,' he said.

These themes were echoed by the following speaker: Nanna Humle, head of quality at Born Donor Bank, who emphasised the need for donor banks to always report new information. She also discussed the issues with screening and the impossibility of testing for everything. Genetic matching could be a future prospect for recessive conditions, she suggested, where exome sequencing allows recipients to see if they carry variants in the same genes as their potential donor. This would, along with worldwide limits and initial genetic screening, create an additional layer of safety.

Rachel Cutting, director of compliance and information at the Human Fertilisation and Embryology Authority (HFEA), followed this presentation, providing perspective from the UK regulator. Cutting explained that the genetic screening of donors mandated by UK law is limited and mostly depends on the donor's personal and familial history. The HFEA's role when incidents – such as the case of donor 7069 – are reported depends on where the donor is from. For UK donors, and those outside the EU, the clinics need to report directly to the HFEA, whereas reports regarding EU donors go through the pan-EU Rapid Alerts for Tissues and Cells system, which alerts the HFEA.

The penultimate speaker, professor of bioethics and health research at the University of Manchester's Centre for Social Ethics and Policy Lucy Frith, focused on the number of children conceived per donor. In addition to genetic issues, she outlined the psychosocial impact on donor-conceived people of overuse of donors, including feelings of commodification and the uncertainty of never knowing when more siblings will be found.

While many countries have national limits on the number of children or families created using gametes from a single donor, these are mostly ineffective since sperm can be exported and used in another jurisdiction once these are reached. Thus, Professor Frith emphasised the need for international limits, but acknowledged these are difficult to monitor and enforce.

The final presentation was from Nina Barnsley, director of the Donor Conception Network, who outlined three issues raised by the case of donor 7069. First, she said, public understanding of screening is often inaccurate. Families and recipients often assume that screening means donors are comprehensively tested and fully cleared, and instead it is important to explain limitations, so expectations are always clear.

Second, Barnsley commented on the scale of the issue: with nearly 200 children conceived with donor 7069's sperm, the case exposes international problems and a need for a more unified process. Finally, she explained how communication must evolve to ensure that such complex and emotionally difficult issues can be discussed even years after conception. Barnsley also spoke about the need to be realistic. While she acknowledged it is easy to call for more education and communication, these all carry costs, and it is important to focus on what can be achieved.

The event concluded with a discussion responding to questions raised by the audience. In response to whether there should be a particular number of families a single donor can create, no one gave a specific answer, but all urged for an international limit. Barnsley and Cutting additionally acknowledged that international collaboration and a bigger conversation are needed for this. Cutting also noted that, while the UK is part of the European Council, it is unclear whether not being part of the EU would affect future collaboration.

Finally, Humle was asked whether such an incident could have happened at Born Donor Bank. She expressed her wish to say no but accepted this could never be certain, and that the case of donor 7069 was a rare and almost impossible investigation to conduct.

All participants also expressed that, while the case of donor 7069 raises several issues worth discussing and learning from, it is important to treat the matter with respect and sensitivity.

---

PET is grateful to the Association of Reproductive and Clinical Scientists, the British Fertility Society, CooperSurgical and Theramex for supporting this event.

Registration is now open for this year's PET Annual Conference – AI and Automation in Fertility and Genomics: Pipeline? Or Pipe Dream? – which is supported by supported by ESHRE, and is taking place in central London on Wednesday 9 December 2026.

Find out more and register here.